COMMUNIQUÉS West-GlobeNewswire

ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa

28/06/2018 - 13:00

The trial, called WINGS, will evaluate the safety and efficacy of QR-313 in subjects with recessive dystrophic epidermolysis bullosa due to mutations in exon 73 of the COL7A1 gene. QR-313 is a first-in-class potential [...]

Dynavax Appoints Scientific Advisory Board to Support its Oncology and Vaccine Programs

28/06/2018 - 12:30

Board Comprises Six Members with Notable Contributions to the Fields of Oncology and Immunology BERKELEY, Calif., June 28, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced the [...]

Hydropothecary reports fiscal 2018 third quarter results

28/06/2018 - 12:30

GATINEAU, Quebec, June 28, 2018 (GLOBE NEWSWIRE) -- The Hydropothecary Corporation (TSX:HEXO) (the "Company") reported its financial results for the three and nine months ended April 30, 2018, the third quarter of the [...]

Hydropothecary déclare les résultats du troisième trimestre de l’exercice 2018

28/06/2018 - 12:30

GATINEAU, Québec, 28 juin 2018 (GLOBE NEWSWIRE) -- La société Hydropothecary (TSX:HEXO) (la « Société ») a publié ses résultats financiers pour les périodes de trois et neuf mois closes le 30 avril 2018, à savoir le [...]

PotNetwork Holdings, Inc. Exhibits Swiftly Growing MediPets Line at Industry Leading SuperZoo Event

28/06/2018 - 12:00

MediPets Comes to Vegas Bringing the Latest in Pet CBD to the Largest Industry Event Geared Toward Professionals and Consumers Seeking Cutting-Edge Products and Education FT. LAUDERDALE, Fla., June 28, 2018 (GLOBE [...]

Amarin Reports Last Patient Study Visit Has Occurred, an Important Step Towards Completion of REDUCE-IT™ Cardiovascular Outcomes Study

28/06/2018 - 11:00

Study Remains On-Track for Q3 2018 Top-Line Results BEDMINSTER, N.J., and DUBLIN, Ireland, June 28, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the [...]

Saniona awarded grant of SEK 1.4 million for Kv7 program

28/06/2018 - 10:40

PRESS RELEASE June 28, 2018 Saniona, a leading biotech company within ion-channel research, today announced that it that it has received a research grant of DKK 1 million (SEK 1.4 million) under the Danish Innovation [...]

Oral semaglutide shows superior reductions in HbA1c and weight compared to sitagliptin in the long-term safety and efficacy trial, PIONEER 3

28/06/2018 - 10:09

Bagsværd, Denmark, 28 June 2018 - Novo Nordisk today announced the headline results from PIONEER 3, a phase 3a trial with oral semaglutide for the treatment of adults with type 2 diabetes. Oral semaglutide is an [...]

Shire plc : Rule 2.9 announcement

28/06/2018 - 08:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 28 June 2018 Shire [...]

Interim report September 1, 2017 - May 31, 2018

28/06/2018 - 08:00

Company announcement no.11/2018 Report attached For further information, please contact: Martin Riise, Head of Investor Relations Tel: +45 53 39 22 50 Helle Rexen, Interim Head of Media Relations Tel: +45 20 74 28 40 [...]

ESPERITE (ESP) : European Select Growth Opportunities Fund subscribes to the 20th tranche of investment today

28/06/2018 - 07:18

Amsterdam, The Netherlands - 28 June 2018 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today a 20 th Tranche of EUR 400,000 is issued as a private placement of 40 convertible notes (the "Notes [...]

Sanofi : Sanofi and Advent finalize negotiations for the acquisition of Zentiva

28/06/2018 - 07:01

Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi and Advent finalize negotiations for the acquisition of Zentiva PARIS - June 28, 2018 - Sanofi and Advent International ("Advent") have finished [...]

Sanofi : Sanofi et Advent finalisent les négociations sur l'acquisition de Zentiva

28/06/2018 - 07:01

Communiqué de presse Source : Sanofi (EURONEXT : SAN) (NYSE : SNY) Sanofi et Advent finalisent les négociations sur l'acquisition de Zentiva Paris - Le 28 juin 2018 - Sanofi et Advent International (« Advent ») [...]

argenx receives second preclinical milestone payment under its development agreement with AbbVie

28/06/2018 - 07:00

June 28, 2018 Breda, the Netherlands/Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]

Forty Seven Prices Initial Public Offering

28/06/2018 - 03:56

MENLO PARK, Calif., June 27, 2018 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq:FTSV), a clinical stage immuno-oncology company, announced today the pricing of its initial public offering of 7,035,000 shares of common [...]

Acasti Pharma Business Update for the Fourth Quarter and Fiscal 2018

27/06/2018 - 23:00

Patient enrollment in the two TRILOGY Phase 3 studies is progressing as planned: 463 patients enrolled and 41 patients randomized at 110 clinical sites as of June 26 th Phase 3 topline results tracking on schedule to be [...]

Novartis International AG: Global study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month

27/06/2018 - 22:31

Study reveals migraine causes significant disruption to daily life and work, which could be managed with better preventive treatments and workplace solutions Migraine is estimated to cost up to €27 billion in Europe and [...]

Imagin Medical Announces Uplisting to OTCQB

27/06/2018 - 22:30

VANCOUVER, British Columbia and BOSTON, June 27, 2018 (GLOBE NEWSWIRE) -- Imagin Medical (CSE:IME) (OTC PINK:IMEXF) (Frankfurt:DPD2) (Stuttgart:DPD2) (“Imagin” or the “Company”) is pleased to announce that its common [...]

Dr. Carrolee Barlow, M.D., Ph.D., Joins Supernus’ Board of Directors

27/06/2018 - 22:30

ROCKVILLE, Md., June 27, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous [...]